POLB vs. SCLP, MPH, HVO, ORPH, REDX, ETX, SBTX, HEMO, COS, and C4XD
Should you be buying Poolbeg Pharma stock or one of its competitors? The main competitors of Poolbeg Pharma include Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), hVIVO (HVO), Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Hemogenyx Pharmaceuticals (HEMO), Collagen Solutions plc (COS.L) (COS), and C4X Discovery (C4XD). These companies are all part of the "biotechnology" industry.
Poolbeg Pharma vs. Its Competitors
Scancell (LON:SCLP) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.
Scancell is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.
Scancell's return on equity of 98.74% beat Poolbeg Pharma's return on equity.
0.9% of Scancell shares are held by institutional investors. Comparatively, 0.6% of Poolbeg Pharma shares are held by institutional investors. 15.2% of Scancell shares are held by insiders. Comparatively, 7.6% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Scancell has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Poolbeg Pharma has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.
In the previous week, Scancell had 4 more articles in the media than Poolbeg Pharma. MarketBeat recorded 4 mentions for Scancell and 0 mentions for Poolbeg Pharma. Scancell's average media sentiment score of 0.75 beat Poolbeg Pharma's score of 0.00 indicating that Scancell is being referred to more favorably in the media.
Summary
Scancell beats Poolbeg Pharma on 6 of the 10 factors compared between the two stocks.
Get Poolbeg Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding POLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Poolbeg Pharma Competitors List
Related Companies and Tools
This page (LON:POLB) was last updated on 9/13/2025 by MarketBeat.com Staff
Free POLB Stock Alerts